Announcements Trials
Browse Landscape

Phase

Phase 3 6Phase 2/3 1Phase 2 1

Status

Completed 4Recruiting 2Enrolling by invitation 1Active not recruiting 1

Sponsor Class

INDUSTRY 7OTHER 1

Study Type

Interventional 8

Sponsor

Conditions

Myasthenia Gravis 8

Interventions

rozanolixizumab 10zilucoplan 8efgartigimod alfa 8Rituximab 7Cyclophosphamide 7telitacicept 6fludarabine 6eculizumab 5Prednisone 5ravulizumab 4Pyridostigmine Bromide 4Immunoglobulins, Intravenous 4Hizentra 4Tacrolimus 3Mycophenolic Acid 3HBM9161 3Amifampridine 3thymoglobulin 2inebilizumab 2Prednisolone 2Exercise 2tofacitinib 1tocilizumab 1talquetamab 1satralizumab 1sargramostim 1rhoA GTP-Binding Protein 1remibrutinib 1prednylidene 1iscalimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

8 trials
RecentStart dateEnrollment
Interventional × Myasthenia Gravis × zilucoplan × Clear all
NCT06055959 2026-05-08

ziMyG

UCB Pharma

Phase 2/3 Recruiting
8 enrolled

Myasthenia Gravis

NCT06435312 2026-05-08

ziMyG+

UCB Pharma

Phase 3 Enrolling by invitation
8 enrolled

Myasthenia Gravis

NCT04225871 2026-04-24

RAISE-XT

UCB Pharma

Phase 3 Active not recruiting
200 enrolled

Myasthenia Gravis

NCT06471361 2026-03-27

A Study to Evaluate the Safe and Effective Use of a Zilucoplan Auto-injector by Study Participants With Generalized Myasthenia Gravis

UCB Pharma

Phase 3 Completed
31 enrolled 11 charts

Myasthenia Gravis

NCT07215949 2026-02-23

Zilucoplan for Severe gMG Exacerbations

Ohio State University

Phase 3 Recruiting
15 enrolled

Myasthenia Gravis

NCT05514873 2025-09-03

An Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of Subcutaneous Zilucoplan in Participants With Generalized Myasthenia Gravis Who Were Previously Receiving Intravenous Complement Component 5 Inhibitors

UCB Pharma

Phase 3 Completed
26 enrolled 14 charts

Myasthenia Gravis

NCT04115293 2025-07-16

RAISE

UCB Pharma

Phase 3 Completed
174 enrolled 19 charts

Myasthenia Gravis

NCT03315130 2022-07-27

Safety and Efficacy Study of RA101495 in Subjects With Generalized Myasthenia Gravis

UCB Pharma

Phase 2 Completed
45 enrolled 21 charts

Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡